Mostrar el registro sencillo del ítem
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
dc.contributor.author | Aurilio, Gaetano | |
dc.contributor.author | Cimadamore, Alessia | |
dc.contributor.author | Mazzucchelli, Roberta | |
dc.contributor.author | López-Beltrán, Antonio | |
dc.contributor.author | Verri, Elena | |
dc.contributor.author | Scarpelli, Marina | |
dc.contributor.author | Massari, Francesco | |
dc.contributor.author | Cheng, Liang | |
dc.contributor.author | Santoni, Matteo | |
dc.contributor.author | Montironi, Rodolfo | |
dc.date.accessioned | 2020-12-10T12:32:15Z | |
dc.date.available | 2020-12-10T12:32:15Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | http://hdl.handle.net/10396/20891 | |
dc.description.abstract | Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androgen ablation therapy is variable, and 20–30% of PCa cases become castration resistant (CRPCa). Several mechanisms can guide treatment resistance to anti-AR molecules. In this regard, AR-dependent and -independent resistance mechanisms can be distinguished within the AR pathway. In this article, we investigate the multitude of AR signaling aspects, encompassing the biological structure of AR, current AR-targeted therapies, mechanisms driving resistance to AR, and AR crosstalk with other pathways, in an attempt to provide a comprehensive review for the PCa research community. We also summarize the new anti-AR drugs approved in non-metastatic castration-resistant PCa, in the castration-sensitive setting, and combination therapies with other drugs. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.source | Cells 2020, 9(12), 2653 | es_ES |
dc.subject | Prostate cancer | es_ES |
dc.subject | Androgen receptor | es_ES |
dc.subject | AR-V7 | es_ES |
dc.subject | AR variants | es_ES |
dc.subject | AR antagonists | es_ES |
dc.subject | AR resistance | es_ES |
dc.title | Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.3390/cells9122653 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |